![David Lee](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
David Lee
Direktor/Vorstandsmitglied bei ITEOS THERAPEUTICS, INC.
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Michel Detheux | M | 57 | 12 Jahre | |
Ann Rhoads | F | 58 | 4 Jahre | |
David Hallal | M | 56 | 6 Jahre | |
Tim van Hauwermeiren | M | 52 | 6 Jahre | |
Robert Iannone | M | 57 | 3 Jahre | |
Tony Ho | M | 58 | 3 Jahre | |
Aaron Davis | M | 45 | 4 Jahre | |
Matthew Call | M | 51 | 5 Jahre | |
Olivier Laureau | M | 67 |
Servier Pharmaceuticals LLC
![]() Servier Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Part of Servier SAS, Servier Pharmaceuticals LLC is a privately held pharmaceutical company focused on oncology. The company, based in Boston, MA, was founded in 1954. Servier Pharmaceuticals is committed to innovation and improving the lives of patients, their families, and caregivers. The company invests in research and development to address the unmet needs of patients, particularly in the areas of oncology, cardiovascular diseases, cancers, diabetes, immuno-inflammatory, and neuro-psychiatric diseases. The company offers financial assistance to support patients, advocacy groups, and healthcare professionals. The company strives for transparency in clinical trials and research and development. Servier Pharmaceuticals aims to create a brighter future for all by providing life-saving treatments to a greater number of patients. The company actively seeks alliances, acquisitions, licensing deals, and partnerships to accelerate access to therapies. David K. Lee has been the CEO of the company since 2018. | - |
Jill DeSimone | F | 68 | - | |
Yvonne McGrath | M | 50 | 4 Jahre | |
Matthew Gall | M | 47 | 4 Jahre | |
Philippe Brantegem | M | - | 4 Jahre | |
Samantha Small | F | - |
Servier Pharmaceuticals LLC
![]() Servier Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Part of Servier SAS, Servier Pharmaceuticals LLC is a privately held pharmaceutical company focused on oncology. The company, based in Boston, MA, was founded in 1954. Servier Pharmaceuticals is committed to innovation and improving the lives of patients, their families, and caregivers. The company invests in research and development to address the unmet needs of patients, particularly in the areas of oncology, cardiovascular diseases, cancers, diabetes, immuno-inflammatory, and neuro-psychiatric diseases. The company offers financial assistance to support patients, advocacy groups, and healthcare professionals. The company strives for transparency in clinical trials and research and development. Servier Pharmaceuticals aims to create a brighter future for all by providing life-saving treatments to a greater number of patients. The company actively seeks alliances, acquisitions, licensing deals, and partnerships to accelerate access to therapies. David K. Lee has been the CEO of the company since 2018. | - |
Sylvie Peltier | M | 60 |
Servier Pharmaceuticals LLC
![]() Servier Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Part of Servier SAS, Servier Pharmaceuticals LLC is a privately held pharmaceutical company focused on oncology. The company, based in Boston, MA, was founded in 1954. Servier Pharmaceuticals is committed to innovation and improving the lives of patients, their families, and caregivers. The company invests in research and development to address the unmet needs of patients, particularly in the areas of oncology, cardiovascular diseases, cancers, diabetes, immuno-inflammatory, and neuro-psychiatric diseases. The company offers financial assistance to support patients, advocacy groups, and healthcare professionals. The company strives for transparency in clinical trials and research and development. Servier Pharmaceuticals aims to create a brighter future for all by providing life-saving treatments to a greater number of patients. The company actively seeks alliances, acquisitions, licensing deals, and partnerships to accelerate access to therapies. David K. Lee has been the CEO of the company since 2018. | 6 Jahre |
Adi Osovsky | F | - | 3 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Derek DiRocco | M | 43 | 3 Jahre | |
Scott Burrows | M | 47 |
Shire International GmbH (Switzerland)
![]() Shire International GmbH (Switzerland) Pharmaceuticals: MajorHealth Technology Part of Takeda Pharmaceutical Co., Ltd., Shire International GmbH is a pharmaceutical company based in Zug, Switzerland. The Swiss company develops, manufactures, and markets pharmaceuticals. | 1 Jahre |
Raffaele Baffa | M | 65 |
Servier Pharmaceuticals LLC
![]() Servier Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Part of Servier SAS, Servier Pharmaceuticals LLC is a privately held pharmaceutical company focused on oncology. The company, based in Boston, MA, was founded in 1954. Servier Pharmaceuticals is committed to innovation and improving the lives of patients, their families, and caregivers. The company invests in research and development to address the unmet needs of patients, particularly in the areas of oncology, cardiovascular diseases, cancers, diabetes, immuno-inflammatory, and neuro-psychiatric diseases. The company offers financial assistance to support patients, advocacy groups, and healthcare professionals. The company strives for transparency in clinical trials and research and development. Servier Pharmaceuticals aims to create a brighter future for all by providing life-saving treatments to a greater number of patients. The company actively seeks alliances, acquisitions, licensing deals, and partnerships to accelerate access to therapies. David K. Lee has been the CEO of the company since 2018. | 2 Jahre |
Bart van Rhijn | M | 52 |
Servier Pharmaceuticals LLC
![]() Servier Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Part of Servier SAS, Servier Pharmaceuticals LLC is a privately held pharmaceutical company focused on oncology. The company, based in Boston, MA, was founded in 1954. Servier Pharmaceuticals is committed to innovation and improving the lives of patients, their families, and caregivers. The company invests in research and development to address the unmet needs of patients, particularly in the areas of oncology, cardiovascular diseases, cancers, diabetes, immuno-inflammatory, and neuro-psychiatric diseases. The company offers financial assistance to support patients, advocacy groups, and healthcare professionals. The company strives for transparency in clinical trials and research and development. Servier Pharmaceuticals aims to create a brighter future for all by providing life-saving treatments to a greater number of patients. The company actively seeks alliances, acquisitions, licensing deals, and partnerships to accelerate access to therapies. David K. Lee has been the CEO of the company since 2018. | 3 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigte Staaten | 19 | 95,00% |
Schweiz | 1 | 5,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen